Table 3:
Survey of principal investigators across 95 sites regarding availability and affordability of cirrhosis-related interventions and management strategies
| Site location | China | India | North America* | Europe | Australia | Africa | South America | Middle East | Rest of Asia |
|---|---|---|---|---|---|---|---|---|---|
| No. of sites (n=95) | 24 | 11 | 23 | 6 | 7 | 5 | 7 | 9 | 3 |
| National Insurance | 24 | 2 | 12 | 6 | 7 | 4 | 5 | 9 | 2 |
| Private Insurance | 0 | 9 | 11 | 0 | 0 | 1 | 2 | 0 | 1 |
| LT available in center? | 16 | 10 | 19 | 3 | 1 | 1 | 7 | 6 | 3 |
| >50% of pts can afford LT | 2 | 0 | 15 | 3 | 6 | 0 | 3 | 4 | 2 |
| Number of ICU beds (Median, IQR) ** | 45 (18, 92) | 60 (40, 80) | 30 (22, 54) | 35 (19, 80) | 40 (24, 58) | 8 (5, 10) | 32 (28, 106) | 50.0 (14, 66) | 20 (15, 40) |
| >50% pts can afford ICU | 11 | 2 | 16 | 3 | 6 | 1 | 3 | 4 | 3 |
| Endoscopy after hours available? | 23 | 11 | 22 | 6 | 7 | 1 | 7 | 9 | 3 |
| >50% forgo tests | 1 | 1 | 1 | 0 | 0 | 3 | 1 | 0 | 0 |
| Rifaximin available? | 24 | 11 | 23 | 6 | 7 | 3 | 7 | 9 | 2 |
| >50% can afford rifaximin | 13 | 6 | 13 | 3 | 6 | 1 | 2 | 6 | 1 |
| Terlipressin available? | 23 | 11 | 8 | 6 | 7 | 2 | 7 | 9 | 3 |
| >50% can afford terlipressin | 22 | 7 | 4 | 3 | 6 | 0 | 3 | 4 | 2 |
| >50% can afford albumin | 21 | 5 | 16 | 3 | 5 | 1 | 3 | 4 | 3 |
| Somatostatin or Octreotide available? | 23 | 11 | 23 | 6 | 7 | 2 | 7 | 9 | 3 |
| >50% can afford somatostatin or octreotide | 22 | 6 | 18 | 3 | 6 | 1 | 3 | 4 | 3 |
| Palliative care available | 12 | 4 | 22 | 6 | 7 | 2 | 7 | 6 | 2 |
| >50% can afford palliative care | 7 | 1 | 17 | 3 | 6 | 0 | 3 | 1 | 2 |
*:
includes USA (n=12 sites), Canada (n=3 sites), and Mexico (n=8 sites), LT: liver transplantation, ICU: intensive care unit, Somatostatin and octreotide are medications needed for treating variceal hemorrhage,
**:
p=0.01 for ICU beds. All Canadian sites (n=3) and all but one Mexican site (n=7) had national insurance coverage while only one US-based site of 12 had national insurance.